Abstract: A window pane includes a transmission control layer including a first glass sheet, a second glass sheet, and a liquid crystal material disposed between the first glass sheet and the second glass sheet. Each of the first glass sheet and the second glass sheet has a thickness of about 1 mm or less. A first panel is bonded to the first glass sheet of the transmission control layer. A second panel is bonded to the second glass sheet of the transmission control layer. The transmission control layer is disposed between the first panel and the second panel. The liquid crystal material is controllable to adjust a transmittance of the window pane.

Abstract: The present invention relates to the use of a CD91 polypeptide for detection and quantification of a hemopexin:heme complex in a biological sample, to the use of a CD91 polypeptide for separation of a hemopexin:heme complex from a biological sample and to the monitoring of a hemolysis treatment using a CD91 polypeptide.

Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

Abstract: The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.

Abstract: The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.

Abstract: A method of assessing risk of chronic post-surgical pain (CPSP) in a subject based on genetic factors, non-genetic factors, or a combination thereof. Genetic factors include a genetic profile comprising a combination of single nucleotide polymorphisms (SNPs) in one or more of the specific genes disclosed herein. Non-genetic factors include psychological factors and psychophysical factors. Any of the methods disclosed herein may further comprise applying to the subject a pain management approach based on the subject's risk of developing CPSP.

Abstract: The invention relates to an interactive training module, comprising at least one image-displaying wall (1, 2) with which motion sequences and/or objects can be displayed to a user, at least one position sensing device (7) with which the positions of at least the user's hands can be detected, and a control unit with which these positions can be compared with those which are stored in the control unit, wherein the control unit can display correction information to the user by means of the at least one image-displaying wall (1, 2) on the basis of the difference between the stored position and the detected position.

Abstract: The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.

Abstract: The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed.

Abstract: Extended release formulations of quetiapine and its pharmaceutically salts, and methods for manufacture of the formulations, may include the use of polymers selected for their physical and chemical characteristics. The formulations may include polymers selected to cause solid dosage forms of the formulations to conform to preselected quetiapine release criteria. The formulations may include non-polymer materials that may affect quetiapine release.

Abstract: Compositions and methods for destroying biological agents such as toxins and bacteria are provided wherein the substance to be destroyed is contacted with finely divided metal oxide or hydroxide nanocrystals. In various embodiments, the metal oxide or metal hydroxide nanocrystals have reactive atoms stabilized on their surfaces, species adsorbed on their surfaces, or are coated with a second metal oxide. The desired metal oxide or metal hydroxide nanocrystals can be pressed into pellets for use when a powder is not feasible. Preferred metal oxides for the methods include MgO, SrO, BaO, CaO, TiO2, ZrO2, FeO, V2O3, V2O5, Mn2O3, Fe2O3, NiO, CuO, Al2O3, SiO2, ZnO, Ag2O, [Ce(NO3)3—Cu(NO3)2]TiO2, Mg(OH)2, Ca(OH)2, Al(OH)3, Sr(OH)2, Ba(OH)2, Fe(OH)3, Cu(OH)3, Ni(OH)2, Co(OH)2, Zn(OH)2, AgOH, and mixtures thereof.